{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:43:37Z","timestamp":1791373417867,"version":"4.3.1"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020MH379"],"award-info":[{"award-number":["ZR2020MH379"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019446","name":"Medical and Health Science and Technology Development Project of Shandong Province","doi-asserted-by":"publisher","award":["202101060342"],"award-info":[{"award-number":["202101060342"]}],"id":[{"id":"10.13039\/501100019446","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32200512"],"award-info":[{"award-number":["32200512"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> FLT3 mutations are closely associated with the occurrence of hematological and solid malignancies, especially with acute myeloid leukemia. Currently, several FLT3 inhibitors are in clinical trials, and some have been applied in clinic. However, the safety, efficacy and pharmacodynamics of these FLT3 inhibitors have not been systemically analyzed before.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold>We searched and reviewed clinical trial reports on the monotherapy of 13 FLT3 inhibitors, including sorafenib, lestaurtinib, midostaurin, gilteritinib, quizartinib, sunitinib, crenolanib, tandutinib, cabozantinib, pexidartinib, pacritinib, famitinib, and TAK-659 in patients with hematological and solid malignancies before May 31, 2023.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold>Our results showed the most common adverse events (AEs) were gastrointestinal adverse reactions, including diarrhea, hand-foot syndrome and nausea, while the most common hematological AEs were febrile neutropenia, anemia, and thrombocytopenia. Based on the published data, the mean overall survival (OS) and the mean progression-free survival (PFS) were 9.639 and 5.905 months, respectively. The incidence of overall response rate (ORR), complete remission (CR), partial response (PR), and stable disease (SD) for all these FLT3 inhibitors was 29.0%, 8.7%, 16.0%, and 42.3%, respectively. The ORRs of FLT3 inhibitors in hematologic malignancies and solid tumors were 40.8% and 18.8%, respectively, indicating FLT3 inhibitors were more effective for hematologic malignancies than for solid tumors. In addition, time to maximum plasma concentration (<jats:italic>T<jats:sub>max<\/jats:sub><\/jats:italic>) in these FLT3 inhibitors ranged from 0.7-12.0 hours, but the elimination half-life (<jats:italic>T<jats:sub>1\/2<\/jats:sub><\/jats:italic>) range was highly variable, from 6.8 to 151.8 h.<\/jats:p><jats:p><jats:bold>Discussion: <\/jats:bold>FLT3 inhibitors monotherapy has shown significant anti-tumor effect in clinic, and the effectiveness may be further improved through combination medication.<\/jats:p>","DOI":"10.3389\/fphar.2024.1294668","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T04:37:02Z","timestamp":1715920622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of FLT3 inhibitors in monotherapy of hematological and solid malignancies: a systemic analysis of clinical trials"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuying","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenpeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronglan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-En","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11523-020-00752-8","article-title":"Sunitinib in patients with metastatic colorectal cancer (mCRC) with FLT-3 amplification: results from the targeted agent and profiling utilization registry (TAPUR) study","volume":"15","author":"Al","year":"2020","journal-title":"Target Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/labmed\/lmz094","article-title":"Monocytic maturation induced by FLT3 inhibitor therapy of acute myeloid leukemia: morphologic and immunophenotypic characteristics","volume":"51","author":"Arries","year":"2020","journal-title":"Lab. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/sj.bjc.6602584","article-title":"Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on\/7 days off in patients with advanced, refractory solid tumours","volume":"92","author":"Awada","year":"2005","journal-title":"Br. J. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11523-014-0305-1","article-title":"Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study","volume":"9","author":"Bala\u00f1a","year":"2014","journal-title":"Target Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","article-title":"Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6112","DOI":"10.1158\/1078-0432.CCR-20-1696","article-title":"Pediatric PK\/PD phase I trial of pexidartinib in relapsed and refractory leukemias and solid tumors including neurofibromatosis type I-related plexiform neurofibromas","volume":"26","author":"Boal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3324\/haematol.2010.030452","article-title":"Phase I study of sorafenib in patients with refractory or relapsed acute leukemias","volume":"96","author":"Borthakur","year":"2011","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-007-0498-4","article-title":"A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period","volume":"61","author":"Britten","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1002\/cncr.34493","article-title":"Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial","volume":"128","author":"Brose","year":"2022","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.bbmt.2014.09.007","article-title":"Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia","volume":"20","author":"Chen","year":"2014","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B12","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/oncolo\/oyac083","article-title":"Phase II study of cabozantinib in patients with bone metastasis","volume":"27","author":"Choy","year":"2022","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1200\/jco.2014.32.15_suppl.7027","article-title":"Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed\/refractory acute myeloid leukemia (AML)","volume":"32","author":"Collins","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"","journal-title":"Lancet Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1200\/jco.2016.34.15_suppl.7008","article-title":"Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","article-title":"Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD\u2013mutated, relapsed or refractory AML","volume":"132","author":"Cortes","year":"","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1182\/blood-2006-02-005702","article-title":"Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics","volume":"108","author":"DeAngelo","year":"2006","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles","volume":"50","author":"Di Gion","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00280-011-1798-2","article-title":"Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study","volume":"69","author":"DuBois","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41375-022-01742-7","article-title":"Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA\/FILO","volume":"37","author":"Dumas","year":"2023","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/cncr.31038","article-title":"Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3\/tyrosine kinase domain\/F691 mutation","volume":"124","author":"Fathi","year":"2018","journal-title":"Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","article-title":"A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease","volume":"105","author":"Fiedler","year":"2005","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.20945\/2359-3997000000373","article-title":"Safety and efficacy of sorafenib in patients with advanced thyroid carcinoma: a phase II study (NCT02084732)","volume":"27","author":"Fierro-Maya","year":"2021","journal-title":"Arch. Endocrinol. Metab."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e14351","DOI":"10.15252\/emmm.202114351","article-title":"YAP\/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis","volume":"13","author":"Gao","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","article-title":"Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma","volume":"13","author":"Goodman","year":"2007","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1158\/1078-0432.CCR-19-3239","article-title":"Phase I study of TAK-659, an investigational, dual SYK\/FLT3 inhibitor, in patients with B-cell lymphoma","volume":"26","author":"Gordon","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/hep.30666","article-title":"Sorafenib induces Pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma","volume":"70","author":"Hage","year":"2019","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/dmd.116.072744","article-title":"Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug","volume":"45","author":"He","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s10147-021-02006-7","article-title":"Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"26","author":"Hosono","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/pharmaceutics13050629","article-title":"Population pharmacokinetic modelling and simulation to determine the optimal dose of nanoparticulated sorafenib to the reference sorafenib","volume":"13","author":"Huh","year":"2021","journal-title":"Pharmaceutics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10637-013-0059-0","article-title":"A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis","volume":"32","author":"Jo","year":"2014","journal-title":"Invest. New Drugs"},{"key":"B37","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.v128.22.624.624","article-title":"Updated results from a phase 1 study of TAK-659, an investigational and reversible SYK inhibitor, in patients (pts) with advanced solid tumor or lymphoma malignancies","volume":"128","author":"Kaplan","year":"2016","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-Like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","article-title":"A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13643-023-02255-9","article-title":"Guidance to best tools and practices for systematic reviews","volume":"12","author":"Kolaski","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1182\/blood-2013-02-484832","article-title":"Results of a phase 2 study of pacritinib (SB1518), a JAK2\/JAK2(V617F) inhibitor, in patients with myelofibrosis","volume":"125","author":"Komrokji","year":"2015","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1223929","DOI":"10.3389\/fphar.2023.1223929","article-title":"Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"14","author":"Krawczyk","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jhep.2022.09.006","article-title":"Overall survival and objective response in advanced unresectable hepatocellular carcinoma: a subanalysis of the REFLECT study","volume":"78","author":"Kudo","year":"2023","journal-title":"J. Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40262-016-0461-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of cabozantinib","volume":"56","author":"Lacy","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"B46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10637-019-00745-z","article-title":"A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors","volume":"38","author":"Lee","year":"2020","journal-title":"Invest. New Drugs"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1200\/JCO.2009.21.8487","article-title":"Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers","volume":"27","author":"Lewis","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1159\/000525671","article-title":"Atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma: results from older adults enrolled in the IMbrave150 randomized clinical trial","volume":"11","author":"Li","year":"2022","journal-title":"Liver Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/cpdd.770","article-title":"Effect of food on the pharmacokinetics of quizartinib","volume":"9","author":"Li","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s12072-016-9774-x","article-title":"HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma","volume":"11","author":"Lin","year":"2017","journal-title":"Hepatol. Int."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1182\/blood.2021011582","article-title":"Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression","volume":"138","author":"Lv","year":"2021","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1023\/B:DRUG.0000047103.64335.b0","article-title":"Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor","volume":"23","author":"Marshall","year":"2005","journal-title":"Invest. New Drugs"},{"key":"B53","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ygyno.2018.12.008","article-title":"A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"152","author":"Matulonis","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s10147-022-02283-w","article-title":"Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma","volume":"28","author":"Nakaigawa","year":"2023","journal-title":"Int. J. Clin. Oncol."},{"key":"B56","unstructured":"Clinicaltrials2017"},{"key":"B57","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/CAD.0000000000000366","article-title":"Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults","volume":"27","author":"Nguyen","year":"2016","journal-title":"Anticancer Drugs"},{"key":"B58","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ajh.26447","article-title":"Gilteritinib clinical activity in relapsed\/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors","volume":"97","author":"Numan","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B59","first-page":"5465","article-title":"An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients","volume":"9","author":"O\u2019Farrell","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3324\/haematol.2022.281216","article-title":"A phase Ib trial of mivavotinib (TAK-659), a dual SYK\/FLT3 inhibitor, in patients with relapsed\/refractory acute myeloid leukemia","volume":"108","author":"Pratz","year":"2023","journal-title":"Haematologica"},{"key":"B63","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/03008916221138881","article-title":"A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: the BREAKPOINT trial (Meet-Uro trial 03)","volume":"109","author":"Procopio","year":"2023","journal-title":"Tumori"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.2001.19.5.1485","article-title":"Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C","volume":"19","author":"Propper","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10637-011-9761-y","article-title":"Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors","volume":"30","author":"Semrad","year":"2012","journal-title":"Invest. New Drugs"},{"key":"B67","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11864-022-00952-6","article-title":"Which FLT3 inhibitor for treatment of AML?","volume":"23","author":"Senapati","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s10637-010-9516-1","article-title":"A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma","volume":"30","author":"Shepard","year":"2012","journal-title":"Invest. New Drugs"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","article-title":"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia","volume":"103","author":"Smith","year":"2004","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1182\/bloodadvances.2020001449","article-title":"A phase 1\/2 study of the oral FLT3 inhibitor pexidartinib in relapsed\/refractory FLT3-ITD-mutant acute myeloid leukemia","volume":"4","author":"Smith","year":"2020","journal-title":"Blood Adv."},{"key":"B71","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1158\/1078-0432.CCR-19-1858","article-title":"High FLT3 levels may predict sorafenib benefit in hepatocellular carcinoma","volume":"26","author":"Sun","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1756-8722-4-13","article-title":"Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications","volume":"4","author":"Takahashi","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s12185-019-02709-8","article-title":"Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study","volume":"110","author":"Usuki","year":"2019","journal-title":"Int. J. Hematol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1111\/cas.13749","article-title":"Clinical profile of gilteritinib in Japanese patients with relapsed\/refractory acute myeloid leukemia: an open-label phase 1 study","volume":"109","author":"Usuki","year":"2018","journal-title":"Cancer Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-016-0367-x","article-title":"Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies","volume":"9","author":"Verstovsek","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1177\/0091270008318006","article-title":"Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus","volume":"48","author":"Wang","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1274754","DOI":"10.3389\/fonc.2023.1274754","article-title":"Comparative efficacy and safety of systemic therapy for advanced hepatocellular carcinoma: a systematic review and network meta-analysis","volume":"13","author":"Wu","year":"2023","journal-title":"Front. Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40880-017-0263-y","article-title":"Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial","volume":"36","author":"Xu","year":"2017","journal-title":"Chin. J. Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.biopha.2017.09.088","article-title":"Comparative safety and efficacy of tyrosine kinase inhibitors (TKIs) in the treatment setting of different types of leukemia, and different types of adenocarcinoma","volume":"95","author":"Yazdi","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"B81","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1200\/JCO.2012.42.5223","article-title":"Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e13158","DOI":"10.1111\/cpr.13158","article-title":"Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1\u03b1\/SLC7A11 pathway","volume":"55","author":"Yuan","year":"2022","journal-title":"Cell Prolif."},{"key":"B83","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/cpdd.1240","article-title":"Dosing recommendation based on the effects of different meal types on pexidartinib pharmacokinetics in healthy subjects: implementation of model-informed drug development strategy","volume":"12","author":"Zahir","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review","volume":"8","author":"Zeng","year":"2015","journal-title":"J. Evid. Based Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.3760\/cma.j.issn.0366-6999.20131757","article-title":"Famitinib in metastatic renal cell carcinoma: a single center study","volume":"126","author":"Zhang","year":"2013","journal-title":"Chin. Med. J. Engl."},{"key":"B86","doi-asserted-by":"publisher","first-page":"100905","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00280-013-2282-y","article-title":"Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib","volume":"72","author":"Zhou","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1093\/nar\/gkac028","article-title":"Pan-cancer assessment of mutational landscape in intrinsically disordered hotspots reveals potential driver genes","volume":"50","author":"Zou","year":"2022","journal-title":"Nucleic Acids Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1294668\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T04:37:09Z","timestamp":1715920629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1294668\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":88,"alternative-id":["10.3389\/fphar.2024.1294668"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1294668","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"article-number":"1294668"}}